FeesSafety
Pluang+

T. Rowe Price Capital Appreciation Premium Income ETF yields 11% but lags peers, rated 'Do Not Buy' for now

Market News
27 Oct 2026, 00:29 WIB
Seeking Alpha
View Source
Bearish
T. Rowe Price Capital Appreciation Premium Income ETF yields 11% but lags peers, rated 'Do Not Buy' for now

The T. Rowe Price Capital Appreciation Premium Income ETF (TCAL) offers an attractive 11% yield but has underperformed its benchmark and peer funds since its inception. Despite its diversified sector allocation and lower company-specific risk compared to the tech-heavy S&P 500, TCAL's short track record, high turnover, and lagging returns make it less appealing than alternatives like GPIX, SPYI, and FTHI. The fund is currently rated "Do Not Buy" until it can demonstrate stronger performance. Investors are advised to watch for future results before considering TCAL as a viable investment option.

The T. Rowe Price Capital Appreciation Premium Income ETF (TCAL) is noted for its attractive 11% yield but has lagged behind peers. For readers following US stocks, here is Pluang's market snapshot as of Oct 27, 2026 04:11 WIB: out of 150 priced US stocks, 73 rose and 76 fell today. Notable movers include Accenture plc (ACN) at USD 249.14 with a 3.71% decline and 93% sell activity, Bristol-Myers Squibb Co (BMY) at USD 63.38 with a 3.70% rise and 55% buy activity, and FuelCell Energy Inc (FCEL) at USD 11.50 with a 3.51% rise and 56% buy activity.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
1 hour ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
1 hour ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
3 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App